{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["M-CENK","nogapendekin alfa inbakicept (N-803)","gemcitabine"]],"indication":"recurrent platinum-resistant high-grade ovarian cancer","name":"ResQ-209","nct_id":"NCT06710288","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=resq-209-nct06710288. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Gemcitabine plus M-CENK plus N-803","label":"All subjects","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-05","type":"ESTIMATED"},"conditions":["Platinum-resistant Ovarian Cancer"],"enrollment":{"count":20,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Gemcitabine","otherNames":["gemcitabine hydrocholoride","Gemzar"],"type":"DRUG"},{"name":"N-803","otherNames":[],"type":"BIOLOGICAL"},{"name":"M-CENK","otherNames":["Autologous Memory Cytokine Enriched Natural Killer"],"type":"BIOLOGICAL"}],"last_update":"2026-07-01","lead_sponsor":"ImmunityBio, Inc.","official_title":"A Phase 2, Open-label, Single-arm Study Of Autologous Memory Cytokine Enriched Natural Killer (M-CENK) Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-05","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Evaluate Progression Free Survival (PFS)","timeFrame":"Cycle 1 Day 1 through End of Study, up to 2 years"},{"measure":"Evaluate Overall Survival (OS)","timeFrame":"Cycle 1 Day 1 through End of Study, up to 2 years"},{"measure":"Evaluate Objective Response Rate (ORR)","timeFrame":"Cycle 1 Day 1 through End of Study, up to 2 years"},{"measure":"Evaluate Duration of Response (DOR)","timeFrame":"From time of first response to the date of disease progression or death, up to 2 years"},{"measure":"Evaluate Disease Control Rate (DCR)","timeFrame":"Cycle 1 Day 1 through End of Study, up to 2 years"},{"measure":"Evaluate the time to progression or death on the next line of treatment (PFS2) of participants receiving M-CENK adoptive cell therapy and N-803 in combination with gemcitabine.","timeFrame":"Cycle 1 Day 1 through End of Study, up to 2 years"},{"measure":"Evaluate the CA-125 response rate (RR) per Gynecologic Cancer Intergroup (GCIC) CA-125 criteria.","timeFrame":"Cycle 1 Day 1 through End of Study, up to 2 years"}],"references":[],"start_date":{"date":"2024-11-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer","url":"https://clinicaltrials.gov/study/NCT06710288"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/resq-209-nct06710288"}